Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...
Alethio Therapeutics raises USD 90M Series A to advance ATX-011, a G6B antibody for essential thrombocythaemia. Read the ...
Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the full story for what's next.
Cardiol Therapeutics unveils a USD 75M at-the-market equity program after its MAVERIC Phase III trial met enrollment early.
Emvena Therapeutics launches with seed funding from the Penn-BioNTech PxB Fund to build placenta-targeted mRNA medicines.
AbbVie licenses Nxera's oral EP4 agonist NXE0033744 for IBD in a $100M upfront global deal. Read the key terms and what this ...
Novo Nordisk Q3'26 earnings: Neuropathic pain expansion and next-generation obesity pipeline advance
Novo Nordisk Q3 2026 earnings show CagriSema outperforming tirzepatide in weight loss. Explore the full pipeline update, ...
Pfizer Q3 2026 earnings: second positive Elrexfio Phase III readout, atirmociclib tolerability data and mevrometostat delay.
A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up ...
Servier's sevasemten missed its Phase III GRAND CANYON primary endpoint in Becker muscular dystrophy. Read how these results ...
AstraZeneca withdraws its EU application for Truqap in PTEN-deficient prostate cancer after a CHMP provisional opinion. Read ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results